Pharminent

EU tests limits of drug pricing freedom in landmark probe

BRUSSELS/LONDON (Reuters) – The first ever EU antitrust probe into excessive drug pricing is taking the European pharmaceuticals industry into uncharted territory, unnerving some companies and lawyers worried about the reach of market intervention.

http://www.reuters.com/article/us-pharmaceuticals-eu-pricing-analysis-idUSKBN19H1IY

Filed under: Pricing